Gene editing has been used to explore astrocyte-targeted therapy for AD such as the induction of NRF2 using a lentivirus NRF2 vector with reduction of Aβ secretion by astrocytes, normalizes cytokine release, and increases GSH secretion in human Presenilin-1 mutated astrocytes (Oksanen et al., 2020). This evidence concerns the gene PSEN1 and Alzheimer disease.